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Abstract
MATWIN (Maturation and Accelerating Translation With INdustry) is part of the nationwide effort to support cancer
innovation. This unique program is willing to support innovative research projects providing tools, resources, and
staff dedicated to project leaders wishing to optimize the industrial attractiveness of their project. The overall
objective is clear: fight cancer always more effectively.
Origins
The MATWIN platform, Maturation and Accelerating
Translation With Industry, was created in 2009 in
Bordeaux (France), ensuing discussions at the Greater
South West Cancéropôle, one of the seven French Can-
céropôles, who aim to enable better coordination of skills
and resources in cancer research at both the regional and
inter-regional levels. MATWIN was founded to facilitate
collaboration between academics and industry, which are
typically two very separate worlds with different concerns,
especially in France. MATWIN’s goal is to bridge the gap
between the Cancer research community and the pharma-
ceutical industry, thus aiming to accelerate the innovation
process from bench to the bedside (Fig. 1).
Cancer is the leading cause of death in France [1]. One
thousand new cancer diagnoses are made daily in France,
and around 400 people per day die from their cancer. Can-
cer incidence continues to rise, yet, cancer mortality has
decreased over the last 20 years, thanks to advances in
therapeutics and diagnostics. Much is at stake which
is the reason why France has set up three successive
Cancer Plans since 2003. The third one was launched
in 2014 and will make it possible to reinforce advances,
open new paths, and engage innovative project initiatives,
such as MATWIN.
MATWIN process
The MATWIN platform is based on a public-private part-
nership bringing together the seven French Cancéropôles
and 11 of the biggest pharmaceutical companies worldwide:
Amgen, AstraZeneca, Bayer Healthcare, Bristol-Myers
Squibb, Celgene, GSK, Merck Serono, Novartis, Pierre
Fabre, Roche, and Sanofi. This nationwide program is ex-
clusively dedicated to the maturation of early oncology re-
search projects up to the preclinical proof of concept. Since
January 2011, the program has been managed through
a private society MATWIN SAS, with offices located
in Bordeaux, which is now a wholly-owned subsidiary of
the UNICANCER group gathering the 20 French Compre-
hensive Cancer Centers. Using Cancéropôles’ networks,
MATWIN experts identify and qualify patented French
academic research projects in oncology to reinforce proof
of concept and preclinical maturation before transfer to the
pharmaceutical industry. This kind of initiative may be fa-
miliar to American researchers and industries, but it is
quite innovative and unique in continental Europe.
The annual process starts with a nationwide call for
proposals, with a selection of projects based on strict eli-
gibility criteria. Eligible projects are then submitted for
both academic and industrial assessment. Individual
working sessions are organized to increase industrial at-
tractiveness of projects. The selection process ends in
Bordeaux, where individual project auditions are held in
Bordeaux with an international public-private board who
recommends projects matching specific criteria to re-
ceive the “MATWIN label” (Fig. 2).
The MATWIN label acts like a stamp of approval for
projects, making them more attractive for collaborations
or partnerships with MATWIN industrial partners or
external investors. During the whole process, academic
teams are encouraged to be aware of economic challenges
and to better understand the market expectations.
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Results
The process has already proved to be successful: 6 years
since the creation of the MATWIN platform, more than
50 % of the projects selected for final audition by the
MATWIN Board have led to first discussions with in-
dustrial partners (MATWIN partners or not) or have
been restructured into start-ups. Of course, creating a
company is a way of simplifying the discussion with in-
dustrial partners, with clearer issues of trusteeship, and
this is also a mark of a research leader’s credibility and
commitment to the valorization of the research project.
During the 2009–2015 period, MATWIN has led to
the following achievements:
 98 letters of intent received
 57 project applications
 >200 academic and industrial assessments
 33 projects submitted to the MATWIN Board
 16 projects have led to first industrial interest
 >15 start-ups created
 three projects in ongoing maturation process with
industrial partners
 and many other discussions in progress.
A win-win partnership
Through MATWIN, all program stakeholders are com-
mitted to a win-win partnership:
– By integrating the MATWIN program, the project
leader benefits from project assessment (three to five
international industrial and academic assessments
per project), individual high value-added coaching
with pharmaceutical development specialists, and
the opportunity to present the project to a board
that is unique in Europe with top executives from
pharmaceutical companies and oncology key opinion
Fig. 1 MATWIN: linking academia, industry, and patients
Fig. 2 MATWIN Board composition
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leaders. The MATWIN process also offers a signifi-
cant pedagogic added-value opportunity to appropri-
ate tech-transfer issues.
– By accompanying the project leader during the whole
MATWIN process, technology transfer offices have
an excellent opportunity to strengthen and legitimize
their possible funding decision on the project.
– For industrial partners, MATWIN represents a
privileged access to an early innovation shared
platform.
MATWIN thus acts as a clear single window process in
cancer research that contributes to accelerate innovation
transfer to the benefit of patients on a major public health
issue. It has long been said that France lagged behind
countries like the USA regarding research public-private
partnerships which have been part of the economic land-
scape and research culture for a long time in the USA.
France is now clearly trying to make up for this delay,
which is one more reason to encourage an innovative pro-
gram such as MATWIN to bridge once and for all the gap
between academic research and industry.
If you need further information, please visit our web-
site: http://www.matwin.org.
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